Candel Therapeutics (CADL) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Candel Therapeutics

NasdaqGM•Healthcare•Biotechnology

$12.60-0.18(-0.01%)Pre-market

Market Cap

$804.32M

P/B

6.4x

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

How this company scores

WeakMetricSide Score: 33/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (4/25).

Profitability8/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality4/25

Strengths

Long cash runwayInterest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 831.4x5y range 413.9x – 844.2x

Currently above its 7-quarter median.

P/B · 6.4x5y range 1.0x – 8.5x

Currently above its 18-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $804.32M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-71.31M
TTM Op. Income: $-71.99M
Q. Op. Income: $-26.75M
TTM Net Income: $-88.53M
Q. Net Income: $-38.91M
EPS: $-0.52
Shares Out.: $74.13M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-71.31M and TTM operating income of $-71.99M show growth is flowing through to the bottom line. However, net income is negative at $88.53M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -2674600000.0%
Net Margin: -3890500000.0%

Op. margin of -2674600000.0% is down 1556900000.0% YoY — costs are rising relative to revenue. Net margin at -3890500000.0% Across the last 8 quarters, operating margin has fallen for 5 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 6.4x

P/S of 0.0x and P/B of 6.4x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $208.15M
Cash: $201.56M
Long-Term Debt: N/A
Book Value: $126.13M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-17.18M
TTM Free Cash Flow: $-57.32M
FCF Margin: N/A
FCF / Net Income: 0.6

TTM FCF of $-57.32M on $-17.18M in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has fallen for 6 consecutive quarters — a weakening trend.